Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

We described insulin glargine (originator) and insulin glargine-yfgn (biosimilar) treatment patterns, assessed effectiveness and safety outcomes, and identified reasons for switching back to the originator product from the biosimilar. This retrospective study included 328,463 Veterans 18 years of ag...

Cijeli opis

Bibliografski detalji
Glavni autori: Samantha Walczuk, Francesca E. Cunningham, Xinhua Zhao, Diane Dong, Peter A. Glassman, Donald R. Miller, Deborah Khachikian, Anthony Au, Cedric Salone, Kelly Bryan, Qoua Her, Sherrie L. Aspinall
Format: Članak
Jezik:English
Izdano: MDPI AG 2024-03-01
Serija:Pharmacoepidemiology
Teme:
insulin glargine
biosimilar pharmaceuticals
drug safety
Online pristup:https://www.mdpi.com/2813-0618/3/1/8

Internet

https://www.mdpi.com/2813-0618/3/1/8

Slični predmeti